Rahman Nasir, Jafary Fahim H
Section of Cardiology, Department of Medicine, Aga Khan University Hospital, Karachi 74800, Pakistan.
Tex Heart Inst J. 2010;37(1):109-12.
Glycoprotein IIb/IIIa inhibitors are established treatment for patients who develop acute coronary syndromes. Thrombocytopenia is known to occur following the administration of various drugs, including heparin and glycoprotein IIb/IIIa inhibitors. In the case of glycoprotein IIb/IIIa inhibitors, the mechanism is thought to be drug-dependent antibodies. In most cases, the thrombocytopenia is mild or moderate in severity. Severe thrombocytopenia (platelet count, <50 x 10(9)/L) is distinctly rare. Herein, we report a case of tirofiban-induced thrombocytopenia in which the overall platelet count dropped precipitously to <1 x 10(9)/L within 12 hours of administration; recovery was relatively prolonged, possibly owing to concomitant renal insufficiency. The severity and the rapidity of onset emphasize the need to routinely check platelet counts early after tirofiban administration, in order to prevent sequelae.
糖蛋白IIb/IIIa抑制剂是治疗急性冠脉综合征患者的既定疗法。已知包括肝素和糖蛋白IIb/IIIa抑制剂在内的各种药物给药后会发生血小板减少症。就糖蛋白IIb/IIIa抑制剂而言，其机制被认为是药物依赖性抗体。在大多数情况下，血小板减少症的严重程度为轻度或中度。严重血小板减少症（血小板计数，<50×10⁹/L）极为罕见。在此，我们报告一例替罗非班诱导的血小板减少症病例，该病例在给药后12小时内血小板总数急剧降至<1×10⁹/L；恢复相对延长，可能是由于合并肾功能不全。其严重程度和发病速度强调了在替罗非班给药后早期常规检查血小板计数的必要性，以预防后遗症。
